August 12, 2020, marked the approval of Viltepso, the 4^th FDA approved therapy for Duchenne. NS Pharma has posted the following community letter marking the occasion. Today we recognize the one-year anniversary of this approval.

Viltepso is approved for individuals amenable to skipping exon 53, representing 8% of individuals with Duchenne. As a community, therapies are currently approved for those amenable to skipping exon 51, 45 or 53. We look forward to continued development of exon skipping therapies including expanding to other exon skipping targets and improving the efficiency of first-generation therapies.

We are grateful for this approval and encourage NS and other sponsors to move forward with their portfolios of additional exon skipping therapies as quickly as possible. We also urge companies with approved therapies to move with expediency to measure the impact of all these therapies in post market and real-world settings.

Read NS Pharma’s Community Letter

August 12, 2021

Dear DMD community,

I want to express our company’s humble appreciation for the community’s enthusiasm and engagement over the past year. Your passion and dedication inspire us in everything we do, and in our mission to develop novel and meaningful treatments for Duchenne.

We continue to work diligently to improve patient access to therapy and innovating potential new treatment options. Over the coming years, we hope to have more milestones and anniversaries to acknowledge as we advance discoveries and expand our knowledge of how to improve the lives of people living with Duchenne.

But today, on behalf of NS Pharma, I want to thank you all for your commitment and collaboration. Together, we are creating a brighter future and redefining what it means to live with Duchenne muscular dystrophy.

Thank you,
Tsugio Tanaka
President,
NS Pharma, Inc.